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the CC BY-NC-ND license (http://creaAbstract Objective: Contemporary prostate cancer (PCa) screening modalities such as pros-
tate specific antigen (PSA) and digital rectal examination (DRE) are limited in their ability to
predict the detection of clinically significant disease. Multi-parametric magnetic resonance im-
aging (mpMRI) of the prostate has been explored as a staging modality for PCa. Less is known
regarding its utility as a primary screening modality. We examined our experience with mpMRI
as both a screening and staging instrument.
Methods: mpMRI studies performed between 2012 and 2014 in patients without PCa were
cross-referenced with transrectal ultrasonography (TRUS) biopsy findings. Statistical analyses
were performed to determine association of mpMRI findings with overall cancer diagnoses
and clinically significant (Gleason score 7) disease. Subgroup analyses were then performed
on patients with a history of prior negative biopsy and those without a history of TRUS biopsy.
mpMRI studies were also cross-referenced with RP specimens. Statistical analyses determined
predictive ability of extracapsular extension (ECE), seminal vesicle involvement (SVI), and
pathologic evidence of clinically significant disease (Gleason score 7).
Results: Four hundred biopsy naı¨ve or prior negative biopsy patients had positive mpMRI
studies. Overall sensitivity, specificity, positive and negative predictive values were 94%,
37%, 58%, and 87%, respectively and 95%, 31%, 42%, and 93%, respectively for overall cancer
detection and Gleason score 7 disease. In patients with no prior biopsy history, mpMRIll.edu (L. Richstone).
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for all cancers, and 95%, 30%, 50%, and 89% for Gleason score7 lesions, respectively. In those
with prior negative biopsy sensitivity, specificity, positive and negative predictive values were
94%, 37%, 52%, and 90% for all cancers, and 96%, 32%, 36%, and 96% for Gleason score 7 le-
sions, respectively. Seventy-four patients underwent radical prostatectomy (RP) after mpMRI.
Lesion size on mpMRI correlated with the presence of Gleason score 7 cancers (p Z 0.005).
mpMRI sensitivity, specificity, positive and negative predictive values were 84%, 39%, 81%, and
44% respectively, for Gleason 7 cancer. For ECE and SVI, sensitivity and specificity were 58%
and 98% and 44% and 97%, respectively.
Conclusion: mpMRI is an accurate predictor of TRUS biopsy and RP outcomes. mpMRI has sig-
nificant potential to change PCa management, particularly in the screening population, in
whom a significant proportion may avoid TRUS biopsy. Further studies are necessary to deter-
mine how mpMRI should be incorporated into the current PCa screening and staging paradigms.
ª 2017 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
An 180,890 new prostate cancer (PCa) diagnoses and 26,120
PCa-related deaths are estimated for 2016 [1]. Unfortu-
nately, contemporary screening and diagnostic in-
struments, such as prostate specific antigen (PSA) and
digital rectal examination (DRE), have limited ability to
differentiate clinically significant disease from benign
conditions or indolent disease. Resultant biopsy exposes
patients to potential for life-threatening infection, in
addition to under detection of clinically significant disease
and over detection of clinically indolent disease, leading to
uncertainty regarding management strategies [2].
Multiparametric magnetic resonance imaging (mpMRI)
has an emerging role in multiple aspects of PCa manage-
ment. Although mpMRI has become well established in
recent years as both a diagnostic and staging tool, its role in
the pre-biopsy setting is not well defined. In current clinical
methodology, risk factors guide the decision to proceed to
biopsy, despite detailed evidence that those same factors,
when incorporated into nomograms, perform poorer than
mpMRI in clinical staging of known PCa [3,4].
mpMRI screening in biopsy-naı¨ve patients with elevated
PSA or abnormal DRE has several theoretical advantages.
Pre-biopsy MRI may allow for the detection of cancer foci
and increase biopsy yield on cognitive or fusion-targeted
biopsy. mpMRI may also be able to obviate the need for
biopsy, if able to accurately discriminate clinically relevant
disease from indolent or absent cancer. This modality also
may have value in patients with one or more negative ul-
trasound guided biopsies and persistently elevated PSA
and/or abnormal exam. It is well established that repeated
transrectal biopsies in this setting have sequentially worse
cancer detection rates [5]. Because the entire prostate is
imaged on mpMRI, suspicious lesions may be detected in
areas of the prostate that may be under sampled, such as
the anterior, apical and central zones. Finally, pre-biopsy
mpMRI affords the clinician the ability to perform a tar-
geted biopsy. Targeted MRI-ultrasound (US) fusion biopsy of
the prostate has been shown to more accurately diagnose
more intermediate and high-risk cancers and fewerindolent, low-risk tumors versus standard, systematic bi-
opsy [6,7]. A targeted-only biopsy strategy may be also
advantageous in the reduction of unnecessary biopsy cores
versus systematic biopsy, potentially limiting biopsy-
related morbidity [7].
Despite the purported advantages of mpMRI in the pre-
biopsy setting, controversy persists. A recent systematic
review found a high rate of both false positives and nega-
tives for mpMRI in the screening population [8]. Given the
discrepancy between theoretical advantages and the actual
benefit of screening MRI, we sought to assess our own
institutional experience with mpMRI as a screening instru-
ment (i.e., patients without prior biopsy or history of
negative biopsy). Additionally, we examined our institu-
tional mpMRI staging accuracy, comparing mpMRI findings
with whole mount radical prostatectomy (RP) specimens.
2. Materials and methods
2.1. Study design
A query of our prospectively maintained, Institutional Re-
view Board-approved database of 1722 3-Tesla (T) mpMRI
was performed within the Northwell Health System. All
mpMRI imaged were acquired with an endorectal coil and
phase array cardiac coil. mpMRI findings were interpreted by
MRI trained uro-radiologists. mpMRI sequences captured
included T1 and T2-weighted, dynamic contrast enhanced
(DCE), and diffusion weighted imaging (DWI). A radiograph-
ically “positive” study was characterized by the presence of
one or more suspicious lesion(s). Additional MRI variables
recorded included number of lesions, lesion size, and loca-
tion by zone, prostate imaging reporting and data system
(PIRADS) scores, apparent diffusion coefficient (ADC), and
overall study suspicion score. Suspicion score consisted of a
5-point Likert scale corresponding to the overall risk of
clinically significant cancer per the recommendations of the
European Society of Urogenital Radiology (ESUR) [9].
Studies were cross-referenced with RP specimens with
patients having undergone RP between 2012 and 2014.
Table 1 Predictive value of mpMRI in screening
population.
Variable Overall PCa
(95% CI)
Gleason 7
(95% CI)
Prevalence 0.48 (0.44, 0.53) 0.34 (0.30, 0.39)
Sensitivity 0.94 (0.90, 0.97) 0.95 (0.91, 0.98)
Specificity 0.37 (0.31, 0.43) 0.31 (0.26, 0.36)
PPV 0.58 (0.53, 0.63) 0.42 (0.37, 0.47)
NPV 0.87 (0.79, 0.92) 0.93 (0.87, 0.97)
CI, confidence interval; mpMRI, multi-parametric magnetic
resonance imaging; NPV, negative predictive value; PCa, pros-
tate cancer; PPV, positive predictive value.
Table 2 Predictive value of mpMRI in biopsy naı¨ve and
prior negative biopsy patients.
Variable Overall PCa
(95% CI)
Gleason 7
(95% CI)
Biopsy naı¨ve
Prevalence 0.56 (0.49, 0.62) 0.42 (0.36, 0.49)
Sensitivity 0.94 (0.88, 0.97) 0.95 (0.88, 0.98)
Specificity 0.36 (0.27, 0.46) 0.30 (0.22, 0.38)
PPV 0.65 (0.58, 0.72) 0.50 (0.42, 0.57)
NPV 0.82 (0.68, 0.92) 0.89 (0.76, 0.96)
Prior negative biopsy
Prevalence 0.42 (0.36, 0.48) 0.28 (0.23, 0.34)
Sensitivity 0.94 (0.88, 0.98) 0.96 (0.89, 0.99)
Specificity 0.37 (0.30, 0.45) 0.32 (0.26, 0.39)
PPV 0.52 (0.45, 0.59) 0.36 (0.29, 0.42)
NPV 0.90 (0.80, 0.96) 0.96 (0.88, 0.99)
CI, confidence interval; mpMRI, multi-parametric magnetic
resonance imaging; NPV, negative predictive value; PCa, pros-
tate cancer; PPV, positive predictive value.
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by trained uro-pathologists.
2.2. Statistical analysis
Descriptive statistics are presented as counts and per-
centages for categorical variables and as means and stan-
dard deviations (SD) for continuous variables. The
association of MRI-related variables with pathology Gleason
score (<7 or 7) was analyzed with Student’s t test for
continuous data and chi-square test for categorical vari-
ables in univariable analysis. The following MRI-related
variables were evaluated in patients who subsequently
underwent RP: number of lesions (continuous), primary
lesions size (continuous, in mm), zone (central or periph-
eral), ADC (continuous, in 106 mm2/s), T2 PIRADS RP score
(1e5), diffusion PIRADS score (1e5), enhancement PIRADS
score (1e5) and overall lesion score (1e5). MRI findings
(positive vs. negative studies) were cross-referenced with
pathologic outcomes to identify predictive properties of a
positive MRI to identify pathologic Gleason score 7 PCa.
Similarly, predictive properties of the presence of extrac-
apsular extension (ECE) and seminal vesicle invasion (SVI)
on MRI to identify pathology-proven extracapsular exten-
sion and seminal vesicle invasion at the time of RP were
also evaluated.
In the pre-biopsy setting, MRI findings (positive vs.
negative studies) were cross referenced with biopsy out-
comes to evaluate the predictive properties of a positive
MRI to identify post-MRI biopsy Gleason score 7 PCa and
post-MRI positive prostate biopsy (any Gleason). Subgroup
analyses, based upon the presence or absence of prior
transrectal ultrasonography (TRUS) biopsy, were performed
to examine predictive abilities in individual patient co-
horts. Estimates are presented with 95% confidence interval
(CI). All statistical analyses were two-tailed and performed
using R 3.2.2 (R Foundation for Statistical Computing,
Vienna, Austria). A p value < 0.05 was considered statisti-
cally significant.
3. Results
3.1. Screening
A total of 513 patients with no prior PCa diagnosis, either
biopsy naı¨ve or prior negative biopsy, underwent an mpMRI
and were subsequently biopsied. Of these patients, 400
(78.0%) had positive mpMRI studies. The overall preva-
lence of PCa on biopsy following mpMRI was 48%, while the
overall presence of Gleason score 7 cancers was 34%. For
overall PCa prediction of biopsy, sensitivity, specificity,
positive predictive value (PPV), and negative predictive
values (NPV) were 94%, 37%, 58%, and 87%, respectively. In
regards to Gleason 7 cancers, sensitivity, specificity,
PPV, and NPV were 95%, 31%, 42%, and 93%, respectively
(Table 1).
In subgroup analyses, 282 patients had a history of
negative biopsy predating mpMRI, while 231 patients had no
prior biopsy history. Overall prevalence of PCa in biopsy
naı¨ve patients was 55%, while Gleason score 7 cancer
prevalence was 42%. In those with a history of negativebiopsy PCa prevalence was 42% for all cancers and 28% for
Gleason score 7 cancers. In patients with no prior biopsy
history, mpMRI sensitivity, specificity, PPV and NPV were
94%, 36%, 65%, and 82%, for all cancers, and 95%, 30%, 50%,
and 89% for Gleason 7 lesions, respectively. In those with
prior negative biopsy sensitivity, specificity, PPV and NPV
were 94%, 37%, 52%, and 90% for all cancers, and 96%, 32%,
36%, and 96% for Gleason 7 lesions, respectively (Table 2).
3.2. Staging
A total of 74 patients underwent RP after mpMRI. Patho-
logic analyses revealed 56 patients with Gleason 7 cancer,
24 with ECE, and 9 with SVI. Overall mpMRI lesion size
correlated with the finding of clinically significant PCa
(Gleason score 7) versus indolent disease on biopsy
(p Z 0.005) (Table 3). No other singular mpMRI character-
istic was significant in discrimination of Gleason 7 from
Gleason <7 cancer on RP specimen, although both DCE
PIRADS score and overall lesion suspicion score approached
statistical significance (p Z 0.054). Analysis of combined
factors was limited due to low numbers. Overall sensitivity,
Table 3 Prostate MRI characteristics by pathology Glea-
son score.
Variable <7 7 p
N (%) 18 (24.3) 56 (75.7)
Number of lesions 0.192
0 8 (44.4) 11 (19.6)
1 5 (27.8) 28 (50.0)
2 5 (27.8) 12 (21.4)
3 0 (0.0) 3 (5.4)
4 0 (0.0) 2 (3.6)
Primary lesion
Size (mm)a 10.7  4.0 16.2  8.5 0.005
ADC (106 mm2/s)a 1124.6 
575.2
677.7 
210.0
0.158
Zone 1.000
Central 2 (20.0) 9 (20.0)
Peripheral 8 (80.0) 36 (80.0)
T2 PIRADS score 0.203
3 2 (50.0) 4 (14.8)
4 2 (50.0) 15 (55.6)
5 0 (0.0) 8 (29.6)
Diffusion PIRADS score 0.598
3 0 (0.0) 1 (3.7)
4 1 (25.0) 4 (14.8)
5 3 (75.0) 22 (81.5)
Enhancement PIRADS score 0.054
1 1 (25.0) 0
2 1 (25.0) 1
3 0 (0.0) 4
4 2 (50.0) 22
Overall lesion score 0.054
3 2 (50.0) 2 (7.4)
4 2 (50.0) 16 (59.3)
5 0 (0.0) 9 (33.3)
MRI, magnetic resonance imaging; PIRADS, prostate imaging e
reporting and data system; SD, standard deviation.
a Values presented as mean  SD, with others as n (%).
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cers was 84%, 39%, 81%, and 44%, respectively. Similarly,
sensitivity, specificity, NPV and PPV were 58%, 98%, 93%,
and 81%, for ECE, and 44%, 97%, 67%, and 93%, for SVI,
respectively.
4. Discussion
In this study we have demonstrated the ability of MRI to
predict outcomes of TRUS biopsy. Excellent negative pre-
dictive capabilities have been demonstrated. Perhaps the
most critical finding is 93% NPV of Gleason score 7 cancers
for all patients. Based on this result, an important consid-
eration for the use of mpMRI in the biopsy naı¨ve and prior
negative biopsy population is the value of a negative scan.
Multiple studies have examined the NPV of negative mpMRI,
ranging between 63% and 98%, for clinically significant
disease [10,11].
Wysock et al. [12] recently reported on 75 patients with
negative mpMRI prior to biopsy. In the subset of biopsy
naı¨ve men, NPV was 81.3% for all cancer detection and98.7% for Gleason sum 7. Similar results were detected in
the prior negative biopsy group, in which NPV was 86.2%
and 100% for all cancers and Gleason sum 7, respectively.
Ultimately, these findings suggest negative mpMRI may
negate the need for TRUS biopsy in select biopsy naı¨ve
patients or those with a history of prior negative biopsy. In
our subset of 282 patients with prior negative biopsies, NPV
was 90% for all PCa and 96% for Gleason 7 cancers. In this
cohort, 24% of men had a negative MRI, indicating 24% of
biopsies may have been avoided at the cost of seven missed
cancer diagnoses, three of which would have been high
grade (Gleason 7) lesions. Similar results were found in
the biopsy naı¨ve group in which the NPVs were 82% and 89%
for PCa and Gleason 7 PCa, respectively, and 19.4% of
biopsy naı¨ve patients had a negative mpMRI. If biopsy was
avoided in these patients, eight cancers and five Gleason
7 cancers would have been undiagnosed.
Apart from the reduction in number of biopsies per-
formed and associated complications, an initial mpMRI
approach may translate to cost savings. Lotan et al. [13]
developed a cost comparison model comparing mpMRI
versus repeat biopsy in men with prior negative biopsy. The
authors found the mpMRI arm to be associated with 73
fewer biopsies per 100 men versus the TRUS arm, while
diagnosing four fewer cancers. Incorporating cost of com-
plications into analysis, this translated to an overall US
$2700 cost savings for the mpMRI arm [13]. Use of a higher
PSA threshold prior to initiation of mpMRI and subsequent
fusion biopsy has been suggested to further increase the
accuracy of identifying patients likely to harbor clinically
significant disease [14].
Some have advocated for the use of MRI as a first line
screening method. A pilot study by Nam et al. [15]
demonstrated a higher odds ratio of PCa for MRI versus
PSA in an unselected screening population. Additionally, a
66.7% PPV was found in those with normal PSA (<4 ng/mL)
and MRI suspicion scores of 4. Similarly, in those with
normal PSA and suspicion scores 3, NPV was 85.7%. Find-
ings in our screening cohort are similar, with few missed
high grade PCa diagnoses. Although the cost of such a
screening program would be astronomical, this study
certainly demonstrates the predictive capability of MRI in
the pre-biopsy setting. Also, despite the low likelihood, the
potential for undiagnosed high grade PCa remains despite
negative mpMRI in the screening population. Patients
should be counseled regarding this risk if biopsy is to be
avoided.
Despite these purported advantages, controversy
regarding the use of mpMRI in the pre-biopsy setting con-
tinues. Recent systematic review of biopsy-naı¨ve patients
revealed 6%e32% false negative and 28%e79% false positive
rates of mpMRI for detection of clinically significant cancer
in patients who subsequently underwent targeted biopsy
[8]. These findings led the authors to not recommend the
use of mpMRI in the biopsy-naı¨ve population. Additionally,
benefit of mpMRI followed by targeted biopsy in the setting
of previous negative systematic biopsy versus repeat sys-
tematic biopsy showed statistical significance in only four
included studies.
In contrast, Meng et al. [16] retrospectively found pre-
biopsy mpMRI followed by targeted biopsy allowed the
detection of more high-grade lesions, while limiting
72 G. Gaunay et al.detection of those Gleason 6 versus that of standard sys-
tematic biopsy. It was their contention that mpMRI should
be considered to identify patients in whom low risk disease
is likely and biopsy may not be warranted. Prospective
comparison of mpMRI with guided biopsy versus TRUS biopsy
in a group of 223 biopsy-naı¨ve men with elevated PSA by
Pokorny and colleagues [17] found a reduction in the diag-
nosis of low-risk cancer by 89.4%, and an increase in the
diagnosis of intermediate and high-risk disease by 17.7%.
The MRI guided biopsy pathway was associated with a
reduction in the need for biopsy of 51% [17]. Similarly, in a
prospective analysis, Numao et al. [18] found mpMRI valu-
able in the pre-biopsy setting to reduce the number of initial
prostate biopsies, particularly in the low-risk (PSA <10 ng/
mL and normal DRE) study cohort. Within this cohort, the
frequency of significant cancer was 9%e13% and 43%e50%
for negative and positive mpMRI, respectively. Within the
high-risk group, frequency ranged from 47% to 51% with
negative mpMRI and 68%e71% with a positive study. These
findings argue for the use of risk assessment nomograms in
the consideration of mpMRI prior to biopsy [18]. Mendhiratta
et al. [19] found mpMRI followed by targeted biopsy had a
higher rate of overall cancer (21.7% vs. 18.6%) and Gleason
score7 (92.3% vs. 57.7%) detection in patients with one or
more negative biopsies, underscoring the importance of
mpMRI and potentially negating the need for additional
systematic biopsy in this population.
mpMRI use in the setting of prior negative biopsy is well
supported as an alternative to repeat systematic biopsy.
mpMRI has been shown to diagnose and discriminate
clinically significant disease in patients with negative
prostate biopsies and persistently elevated PSA who sub-
sequently underwent transperineal systematic biopsies,
suggesting negative mpMRI may be sufficient evidence to
defer additional repeat biopsy [20]. Further, a study of
117 patients, all with at least one prior negative biopsy
and PSA >4.0 ng/mL, demonstrated a prostate PCa-
detection rate of 41%. More significantly, the vast major-
ity, 87%, was considered clinically significant by Epstein
and d’Amico classification. However, of the nine patients
in whom PCa was detected after negative MRI guided bi-
opsy, 78% were found to have clinically significant disease,
suggesting a role for continued surveillance of those with
elevated PSA and negative MRI guided biopsy [21].
While the use of mpMRI in the pre-biopsy setting remains
open to debate, the use of staging MRI with diagnosed PCa
is better established. In this study we have demonstrated
the association of tumor size on mpMRI with clinically sig-
nificant disease on RP specimen. Additionally, DWI PIRADS
and overall study ESUR scoring approached significance.
mpMRI has been shown to improve upon risk assessment
nomograms in the determination of tumor extent [3,22]. A
number of studies have compared mpMRI with histopatho-
logic findings after RP. De Rooij et al. [23] pooled these
findings in a recent meta-analysis, demonstrating excellent
specificity between 88% and 96% for detection of ECE, SVI,
and overall T3 disease status. Unfortunately, it is hampered
by weak sensitivity ranging between 57% and 61% for similar
pathologic findings [23]. Predictive capabilities as
described in this study showed similar limited sensitivity,
likely owing to inability to accurately detect microscopic
extraprostatic disease on mpMRI.Functional imaging has been found to improve overall
sensitivity, and the use of at least two functional modalities
is recommended [9,23,24]. T2-weighted imaging, used in
conjunction with functional sequences (i.e., DWI, DCE, and
MR spectroscopy (MRSI)), has been shown capable of tumor
detection and risk categorization [25,26]. While T2-
weighted imaging versus combined T2 and DWI may be
similarly capable in tumor detection, DWI may provide
additional information regarding tumor aggressiveness [27].
ADC determined by DWI has been inversely correlated with
biopsy Gleason score [28e30]. ADC values have been shown
able to discriminate low risk disease (Gleason <7) from
intermediate-high risk cancers (Gleason 7), while negative
T2-weighted and DWI sequences are associated with a high
rate of negative biopsy [30e33]. Interestingly, in our study
ADC values were not significantly correlated to RP specimen
Gleason scores, potentially owing to low study numbers.
mpMRI may also be useful in selection of patients for
active surveillance (AS) protocol. Suspicious mpMRI can
demonstrate the presence of clinically significant disease
amongst the AS population [27,34]. Patients with index le-
sions, defined as cancer within the same sextant on biopsy
in two separate surveillance biopsies, had a higher rate of
biopsy reclassification. Lack of an index lesion may provide
further evidence for the presence of indolent disease in the
AS population, potentially negating the need for repeat
biopsy [35]. Low-risk findings on ADC mapping may influ-
ence the decision for repeat biopsy in the AS population.
This study has several limitations. mpMRI findings along
with pathologic analyses were from a single institution’s
experience and may not be replicable. Overall number of
RP specimens was low, limiting statistical power, including
the analysis of combined mpMRI parameters. Further
research through prospective trials is necessary to deter-
mine the role of mpMRI specifically within the biopsy-naı¨ve,
staging population before mainstream acceptance. Addi-
tional considerations such as MRI expense and patient
quality of life must be included in the cost-benefit analyses
prior to alteration of the current PCa-screening paradigm.
5. Conclusion
Large lesions on mpMRI were predictive of clinically signifi-
cant disease at the time of RP, however variable accuracy
was exhibited in the prediction of ECE, SVI, and Gleason 7
disease. mpMRI may be predictive of TRUS biopsy results in a
screening population, with a 93% NPV, suggesting that TRUS
biopsy may be avoided in select patients with normal
studies. Further large, prospective trials are needed to
determine the role of mpMRI in a screening population.
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